A Study to Evaluate the Dose Response Based on the Efficacy, Safety and Tolerability of Bimekizumab in Subjects With Active Psoriatic Arthritis Which is a Type of Inflammatory Arthritis
Clinical trial NCT02969525 · COMPLETED
Trial details
- NCT number
- NCT02969525
- Sponsor
- UCB Biopharma S.P.R.L.
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2016-10-01
- Primary completion
- 2017-11-01
- Enrollment
- 206
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.